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Abstract
The genetic causes of congenital hypothyroidism due to thyroid
dysgenesis (TD) remain largely unknown. We identified three novel
TUBB1 gene mutations that co-segregated with TD in three distinct
families leading to 1.1% of TUBB1 mutations in TD study cohort.
TUBB1 (Tubulin, Beta 1 Class VI) encodes for a member of the b-
tubulin protein family. TUBB1 gene is expressed in the developing
and adult thyroid in humans and mice. All three TUBB1 mutations
lead to non-functional a/b-tubulin dimers that cannot be incorpo-
rated into microtubules. In mice, Tubb1 knock-out disrupted micro-
tubule integrity by preventing b1-tubulin incorporation and
impaired thyroid migration and thyroid hormone secretion. In
addition, TUBB1 mutations caused the formation of macroplatelets
and hyperaggregation of human platelets after stimulation by low
doses of agonists. Our data highlight unexpected roles for b1-
tubulin in thyroid development and in platelet physiology. Finally,
these findings expand the spectrum of the rare paediatric diseases
related to mutations in tubulin-coding genes and provide new
insights into the genetic background and mechanisms involved in
congenital hypothyroidism and thyroid dysgenesis.
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Introduction
Thyroid dysgenesis (TD) is a feature in 65% of patients with
congenital hypothyroidism (CH), the most common neonatal endo-
crine disorder affecting one in 2,500–3,500 newborns (Deladoe¨y
et al, 2011; Barry et al, 2016). In France, the prevalence of CH due
to TD is estimated in 1/5,000 (Barry et al, 2016). TD includes a vast
spectrum of developmental thyroid anomalies encompassing athyre-
osis, thyroid ectopia, hypoplasia of an orthotopic gland, and
hemithyroid (Barry et al, 2016; Stoupa et al, 2016). During embryo-
genesis, the midline thyroid anlage appears on embryonic day E.8.5
in mice and at 3 gestational weeks (GW) in humans. The midline
anlage and ultimobranchial bodies migrate and fuse in the definitive
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pretracheal position on E13.5 in mice and at 7 GW in humans
(Trueba et al, 2005; Nilsson & Fagman, 2013). The cells differentiate
into thyrocytes organized in follicles or C cells (Appendix Table S1;
Szinnai et al, 2007). Abnormalities at any step of thyroid develop-
ment may result in TD associated with hypothyroidism or not
(Maiorana et al, 2003). Previous studies of sporadic and familial TD
covering a wide clinical spectrum identified mutations in nine
genes: PAX8, NKX2-1, FOXE1, NKX2-5, TSHR, GLIS3, NTN1, JAG1
and BOREALIN (Dentice et al, 2006; Sene´e et al, 2006; Carre´ et al,
2009, 2014, 2017; Sura-Trueba et al, 2009; Ramos et al, 2014; Opitz
et al, 2015; de Filippis et al, 2016). However, mutations in these
genes are found in only 5% of all patients with TD and identification
of causative mutations remains a challenging task. Our objectives
were to extend the knowledge on the genetic basis of CH and TD.
We performed WES (whole exome sequencing; Choi et al, 2009;
Hildebrandt et al, 2009) for siblings with CH and thereby identified
a mutation in TUBB1 gene. Then, we analysed 270 TD cases by
targeted NGS including the TUBB1 gene. We identified two more
TUBB1 mutations in patients with CH and TD.
TUBB1 (Tubulin, Beta 1 Class VI) encodes for a member of the b-
tubulin protein family. b-tubulins are one of two core protein fami-
lies that heterodimerize to form a/b-tubulin dimers, which assemble
into microtubules, one of the major cytoskeletal structures. The b1
isotype of tubulin (TUBB1) has been described as specifically
expressed in platelets and megakaryocytes and involved in propla-
telet formation and platelet release (Patel et al, 2015). Few muta-
tions of TUBB1 have been identified in patients with a rare
autosomal dominant disease congenital macrothrombocytopaenia,
in which impaired microtubule assembly results in low platelet
counts and macroplatelets (Kunishima et al, 2009; 2014; Bastida
et al, 2018; Johnson et al, 2016; Burley et al, 2018). Tubb1-knock-
out mice have thrombocytopaenia and spherical platelets (Schwer
et al, 2001), but not known thyroid abnormalities. Our results high-
light a hitherto unsuspected role for a specific tubulin isotype,
Tubb1, in thyroid development and disease and extend our knowl-
edge on genetic background of CH.
Results
Identification of TUBB1 mutations in a family with TD
Family F1 is a consanguineous family of Algerian descent. The
parents are first cousins (I.1, I.2) with five children including two
females [II.1 (patient P1) and II.2 (patient P2)] with CH. Both
patients were born at full term and diagnosed with CH by routine
neonatal screening (Fig 1), which showed thyroid-stimulating
hormone (TSH) elevation (164 and 177 lIU/ml in P1 and P2,
respectively). On days 13 and 11, TSH was 67 and 202 lIU/ml in P1
and P2, respectively (normal range, N: 0.3–7 lIU/ml), and free
thyroxine (T4) was 14 and 13.3 pmol in P1 and P2, respectively (N:
9.5–25 pmol; Fig 1). L-thyroxine therapy was initiated. 123I scintig-
raphy showed thyroid ectopia in both siblings. Another sibling (II.5,
P3), aged 12 years, had thyroid hypoplasia (thyroid volume, 3.1 ml;
N: 7  3 ml) with a small right pyramidal lobe (17 *2 mm) and
normal thyroid function tests. The parents had normal thyroid func-
tion, and two other siblings (II.3 and II.4) had normal thyroid func-
tion but were not able to undergo thyroid ultrasonography.
To look for genetic causes of CH in P1 and P2, we performed
whole exome sequencing (WES) using the variant filtering and
prioritization strategy described in Appendix Fig S1. Using the reces-
sive transmission model, WES identified a novel missense homozy-
gous TUBB1 mutation (c.479C>T, p.P160L, rs759117911) in both
siblings with CH (P1 and P2) and in the sibling with thyroid hypo-
plasia (P3; Fig 1). Both parents and sibling II.3 were carriers. The
remaining sibling (II.4) did not carry the mutation. WES identified
no variants in genes known to be associated with TD or thyroid
dyshormonogenesis.
Search for TUBB1 mutations in a cohort with thyroid dysgenesis
(TD) and congenital hypothyroidism (CH)
After identification of the above-described novel TUBB1 mutation,
we used targeted next-generation sequencing (NGS) to assess
TUBB1 in a cohort of 270 patients with CH and TD. In a second
family (F2) with a father (I.2) of Moroccan and a mother (I.1) of
French descent, a female with CH and thyroid gland ectopia (P4,
II.1) had a heterozygous TUBB1 mutation (c.318C>G, p.Y106X;
Fig 1). CH was diagnosed upon routine neonatal screening (TSH,
250 lIU/ml) and confirmed on day 15 (TSH, 1,100 lIU/ml; free T4,
3.5 pmol/l; and free T3, 2.45 pmol/l). Thyroid scintigraphy showed
an ectopic thyroid. The father carried the same heterozygous muta-
tion; unfortunately, thyroid ultrasound was not performed, and
complete phenotype was therefore not possible. In a paternal aunt
(I.3, P5), an evaluation at 26 years of age for obesity and depression
showed mild hypothyroidism (TSH, 6.6 lIU/ml; N: 0.1–5.5 lIU/ml;
free T4, 8.7 pmol/l; N: 9.8–23.1 pmol/l). Thyroid ultrasonography
and scintigraphy showed right hemithyroid.
In a third family (F3), a patient (II.1, P6) with CH and an ectopic
thyroid was shown by targeted NGS to have a heterozygous frame-
shift TUBB1 mutation (c.35delG, p.Cys12Leufs*12, rs77324804) that
created a premature stop codon at amino acid 23 (Fig 1). CH was
diagnosed neonatally based on TSH elevation (476 lIU/ml) and low
free T4 and T3 levels (8 and 5.6 pmol/l, respectively). L-thyroxine
therapy was started at 11 days of age. Both parents were of French
descent. The father (I.1, P7) carried the same heterozygous muta-
tion and had normal thyroid function with mild thyroid lobe asym-
metry by ultrasonography (right lobe, 6.9 ml; left lobe, 5 ml). The
other siblings and mother had normal thyroid function and
morphology and did not carry the mutation.
By targeted NGS, neither P4 nor P6 had any variants in genes
known to cause CH (with TD or dyshormonogenesis).
In the Exome Aggregation Consortium (ExAC) database, esti-
mated allele frequencies are 0.000008 for the c.479C>T mutation
(rs759117911, 20:57598961 C/T) and 0.000025 for the c35delG
(rs773248042, 20:57594611 TG/T) mutation. Neither mutation has
been reported in homozygous form. The c.318C>G variation has not
been reported in public databases. The in silico prediction tools,
PolyPhen-2, SIFT, predict that c.479C>T is probably damaging and
deleterious, respectively, with a PHRED-scaled CADD score of 32
(damaging: > 15; Kircher et al, 2014). The other two mutations
create a premature stop codon and have PHRED-scaled CADD score
of 35. CADD is a prediction algorithm, which integrates information
contained in more than 60 diverse annotations of genetic variation
into a single score. The higher the CADD score, the higher the dele-
teriousness probability of the variant investigated.
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A Burden test was applied to determine whether TUBB1 was
significantly enriched in rare variants in the 270 patients with CH
and TD versus 406 Caucasian controls from the 1000 Genomes
project. The patients in the TD cohort had athyreosis, ectopia,
hemithyroid or hypoplasia. In the TD group, 14/270 patients (5.2%)
exhibited at least one rare functional variant in TUBB1 compared
with 8/406 controls (2%). This difference is significant from a statis-
tical point of view (P = 0.0227). None of the patients in our cohort
with TUBB1 mutations had athyreosis. Performing the same test
after excluding the 77 patients with athyreosis increased the signifi-
cance of the difference of TD group (n = 193) versus controls
(P = 0.0095). The list of rare functional variants found in TUBB1 is
provided in Table EV1.
The three amino acids affected by the TUBB1 mutations are
strictly conserved across species, from humans to zebrafish, and
across all b-tubulins (Fig 2A). All three mutations were located in
the first part of TUBB1, i.e., in the N-terminal domain needed for
guanosine triphosphate (GTP) activity (Fig 2B). The c.318C>G and
c.35delG mutations created a premature stop codon, thereby remov-
ing the intermediate and C-terminal domains required for micro-
tubule-associated protein (MAP) binding (Nogales et al, 1998).
In sum, we identified three TUBB1 mutations in three indepen-
dent families of patients with CH and TD chiefly manifesting as
thyroid gland ectopia. Thus, we found 1.1% of TUBB1 mutations in
patients affected with CH and TD in our cohort.
b1-tubulin is expressed in the developing thyroid in humans
and mice
b1-tubulin expression has so far been reported only in megakary-
ocytes and platelets (Wang et al, 1986; Lecine et al, 2000). Our
finding of TUBB1 mutations in patients with TD prompted us to look
for b1-tubulin expression in thyroid tissue. In human thyroid tissue,
TUBB1 mRNA was expressed at 8, 10 and 12 GW and in adulthood
(Fig 3A). In mouse thyroid tissue, Tubb1 was expressed at E13.5
and strongly at E15.5, E17.5 and adulthood (Fig 3B). To refine our
Figure 1. Pedigrees and clinical table.
Pedigrees of three families with TUBB1 mutations. Family F1 has three affected individuals with homozygous mutations, family F2 has two affected individuals with
heterozygous mutations, and family F3 has two affected individuals with heterozygous mutations. Thus, all seven patients (P1–P7) carry at least one mutated allele and have
thyroid dysgenesis (TD) and macroplatelets. The patients are represented with filled symbols and unaffected family members with open symbols. NA, not available thyroid
ultrasonography; *mild thyroid asymmetry (possibly normal) with normal thyroid function; N, not mutated; m, mutated.
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study of Tubb1 expression, we used cells sorted from mice thyroid
tissue based on well-accepted markers (Gawade et al, 2016) with
stringent sorting regions, including the brightest cells for each
selected marker (Pecam for endothelial cells, EpCAM for epithelial
cells, Pdgfra for fibroblasts and CD45 for leucocytes). As expected,
expression was strongest in platelets sorted using the specific
megakaryocyte lineage marker CD41 (Appendix Fig S2A). However,
Tubb1 was also expressed in EpCAM-positive epithelial-cell popula-
tions containing thyrocytes, at E17.5 and in adulthood (Fig 3C).
Similarly, in human thyroid tissue, immunohistochemistry
showed b1-tubulin expression in the cytoplasm of thyroglobulin
(TG)-producing thyrocytes at 12 GW (Fig 3D). Comparable findings
were obtained with mouse thyroid tissue (Appendix Fig S2B). No
staining was observed in the thyroid tissue of Tubb1/ mice
(Appendix Fig S2C). These data established that b1-tubulin is
expressed in thyrocytes.
Functional in vitro analysis of disease-causing mutations
To further investigate the implication of TUBB1 gene mutations in
thyroid disease, we transfected the mutations into the Nthy-ori 3-1
cell line. Only the c479C>T (p.P160L) mutation could be studied in
this model. The c318C>G (p.Y106X) and c.35delG (p.Cys12Leufs*12)
mutations created premature stop codons that yielded truncated
proteins (Appendix Fig S3) that cannot form functional a/b-tubulin
dimers and thus cannot get incorporated into microtubules (Nogales
et al, 1998; Joe et al, 2009). The pathogenic role of these mutations
is thus loss-of-function.
A
B
Figure 2. Molecular genetics.
A Alignment and conservation of residues encoded by TUBB1 orthologues and genes encoding for other b-tubulins (TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB5,
TUBB6 and TUBB8). Mutations are shown in green. Mutated aminoacids through species or through all TUBB are shown in red boxes.
B Location of TUBB1 mutations in the cDNA and of the corresponding changes in the protein. Exons are represented by boxes numbered from 1 to 4. The dark grey box
represents the protein domain responsible for encoding guanosine triphosphate (GTP) and the light grey box the domain for microtubule-associated protein (MAP)
binding. The arrows show the consequences of the three TUBB1 mutations in our patients, all of which are in the GTP domain. Mutations of this study are in bold,
and published mutations associated with congenital macrothrombocytopaenia are in italic.
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Structural modelling of p.P160L mutant b1-tubulin
To assess the consequences of the P160L mutation on b1-tubulin
function, the sole missense mutation that should give rise to a full-
length protein, we first compared the configurations of the mutated
and wild-type proteins. The P160L mutation is located at the end of
helix H4 (Fig 3E). In wild-type b1-tubulin, the proline residue stabi-
lizes loop H4-S5 and places R156 in a position that promotes a salt
bridge interaction with D197 in the b-sheet S6. Furthermore, R162
in loop H4-S5 and N195 in the b-sheet S6 establish hydrogen bonds
with R156. Mutation of proline 160 to leucine might affect the loop
conformation of the H4-S5 loop and thus disrupting the interaction
network mediated by R156. Hence, the P160L mutation is most
likely affecting the conformation of the b-tubulin, which could lead
to dysfunctions of the a/b-tubulin dimer.
In vitro consequences of the p.P160L b1-tubulin mutation on
microtubule incorporation
Following the predictions from the modelling, we examined the abil-
ity of b1-tubulin P160L protein to incorporate within the micro-
tubule network in the Nthy cell line. We used a vector containing
human TUBB1 cDNA tagged with Myc. We transfected Nthy cells
with the wild-type and P160L mutant then compared the distribu-
tion and location of the protein by double-label immunofluores-
cence (Fig 3F). The overexpressed wild-type b1-tubulin co-
assembled incorporates into microtubules, in contrast to b1-tubulin
P160L (absence of incorporation). Thus, the P160L mutation clearly
affects the capacity of b1-tubulin to incorporate into microtubules,
which is most likely related to defects at the structural level, thus
forming a dysfunctional a/b-tubulin dimer.
A
D E F
B C
Figure 3. b1-tubulin expression in the developing thyroid and deleterious effect of TUBB1 mutations.
A TUBB1 is expressed in the developing human thyroid at 8 gestational weeks (GW), 10 GW and 12 GW and in the adult human thyroid: quantitative PCR results
normalized to one of three thyroid tissues at 8 GW value (in black) and peptidylprolyl isomerase A. Experiments with four tissues per stage. Results are reported as
mean  SEM. Statistical comparisons versus 8 GW (in black) using ANOVA test showed no significant differences.
B Tubb1 is expressed in the developing mouse thyroid at E13.5, E15.5 and E17.5 and in the adult mouse thyroid: quantitative PCR results normalized to one of three
thyroid tissues at E13.5 value and peptidylprolyl isomerase A. Experiments with four tissues per stage. Results are reported as mean  SEM. Statistical comparisons
versus E13.5 (black), **P < 0.01 using ANOVA test.
C Sorted mouse thyroid cells, Tubb1 expression in endothelial cells (Pecam-positive cells), epithelial cells (EpCAM), fibroblasts (Pdgfra) and leucocytes (CD45) at E17.5
and adulthood: quantitative PCR results (normalized to EpCAM-positive cells at adult stage and peptidylprolyl isomerase A). Mean  SEM of three independent cell-
sorting experiments. Statistical comparisons versus epithelial cells (in black) at each stage, *P < 0.05, ***P < 0.001 using ANOVA test.
D Immunohistofluorescence of b1-tubulin (in red), thyroglobulin (TG, in green) and both merged (from left to right) at 12 GW in human thyroid tissue. The boxes
delineate the enlarged areas shown below.
E Structural representation of wild-type and p.P160L mutated b1-tubulin showing the change in conformation surrounding helix H4. Top: proline at position 160 in
pink; bottom: substituting leucine at the same position in blue.
F Localization of transfected Myc-tagged wild-type and mutant (P160L) b1-tubulin in Nthy cells. Immunostaining with anti-Myc antibody (in green) and microtubule
cytoskeleton stained with a-tubulin antibody (in red). Note that b1-tubulin -P160L is found throughout the cytoplasm showing puncta appearance, whereas wild-
type b1-tubulin colocalizes with the microtubules.
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In summary, all three TUBB1 mutations identified here likely
lead to non-functional a/b-tubulin dimers that cannot be incorpo-
rated into microtubules.
Tubb1 knock-out in mice affects thyroid development
and function
The phenotype of patients bearing TUBB1 mutations suggests that
b1-tubulin may contribute to thyroid development and function. We
assessed this hypothesis in Tubb1 knock-out mice (Tubb1/;
Schwer et al, 2001).
We found significant increases in expression levels of the other
b-tubulin isoforms (Tubb2a, Tubb5, Tubb2b and Tubb3) in E17.5
thyroids of Tubb1/ mice compared to wild-type mice
(Appendix Fig S4A). Tubb2b and Tubb3 expression levels were also
increased in adult Tubb1/ mice. In addition, Tuba3 and Tuba4
expression in Tubb1/ mouse thyroids were diminished at E17.5
and in adults. Interestingly, these compensatory changes in
expression levels seen in the thyroid gland mirror those described
in platelets of Tubb1/ mice (Appendix Fig S4A; Schwer et al,
2001).
Thyroid gland development and differentiation
Thyroid gland morphology in mice To study thyroid gland develop-
ment from the early stages of budding and migration of the median
anlage (MA) and ultimobranchial bodies (UB) to the late stages of
differentiation, we used immunohistochemistry, surface quan-
tification and quantitative PCR (Appendix Table S1). For most of the
experiments, we used Nkx2-1 as a marker of progenitor and differen-
tiated thyroid cells. At E9.5, thyroid anlage surface area and prolifer-
ation ratio were significantly greater in Tubb1/ mice than in
wild-type mice (Fig 4A and B, and Appendix Table S2). At E11.5,
thyroid migration was slightly delayed in three of six Tubb1/
embryos, a few Nkx2-1-positive cells were visible along the
migration tract of the mutants, and thyroid surface area was not
different between mutant and wild-type embryos (Fig 4A and B,
and Appendix Table S2). During late thyroid development, at
E13.5, fusion of the median anlage and ultimobranchial bodies was
slightly delayed in three of four Tubb1/ embryos (Fig 4A and
Appendix Table S2). After E13.5, Tubb1/ thyroids were signifi-
cantly hypoplastic (Fig 4A and B). Moreover, at E17.5, a supplemen-
tary pyramidal lobe was visible near the normal lobe in two of six
embryos (Fig 4A). In keeping with this finding, patient P3 in family
1 described above, who was homozygous for the p.P160L mutation,
had a hypoplastic thyroid with a pyramidal lobe. In sum, the thyroid
phenotype of Tubb1/ mice indicates that b1-tubulin is required for
normal thyroid migration and morphology.
Thyroid gene ontogeny in mice We used quantitative PCR to assess
the ontogeny of genes involved in thyroid function and development
(Fig 4C). Expression levels of mRNAs for thyroglobulin (Tg),
thyroid peroxidase (Tpo), TSH receptor (Tshr) and calcitonin
(Calca), late differentiation markers, were significantly decreased at
E15.5, as were those of Tg, Tpo and Calca at E17.5, in Tubb1/
compared to wild-type embryos. Significant decreases were also
observed at E17.5 in the Tubb1/ embryos in the early thyroid
development markers Nkx2-1, Pax8 and Foxe1. These results
indicate impaired thyroid gland development and differentiation in
Tubb1/ mice.
Endocrine signature at completion of thyroid gland develop-
ment T4-positive thyroid surface area relative to total thyroid
surface area was shown by immunohistochemistry to be signifi-
cantly increased at E17.5 in Tubb1/ versus wild-type embryos
(Fig 4D). Calcitonin-positive thyroid surface area relative to total
thyroid surface area tended to be greater in the mutants (P = 0.19).
Thus, final thyroid differentiation was abnormal in Tubb1/
embryos, with increases in intrathyroidal T4 that probably reflected
impaired hormone secretion.
These results establish a role for b1-tubulin in thyroid develop-
ment and differentiation.
Thyroid gland function and structure in adult mice
We compared thyroid hormone status in adult Tubb1/ and
wild-type mice. At 3 months of age, serum TSH levels were
higher and T4 levels lower in Tubb1/ than in wild-type mice,
suggesting hypothyroidism in the mutants (Fig 5A). These results
are consistent with the finding of CH in our patients carrying
TUBB1 mutations.
Furthermore, we examined thyroid structure in adult mice
(3 months of age). Surface area was not different between the
Tubb1/ and wild-type thyroids (data not shown). Moreover, the
thyroid tissue was disorganized in the mutants with large regions
without organized follicles (Fig 5B). When we used electron micro-
scopy to examine thyrocyte ultrastructure (Fig 5C), we found larger
numbers of dense and rod-shaped vesicles in Tubb1/ compared
to wild-type thyrocytes. These data were consistent with impaired
T4 release responsible for hypothyroidism. Marked endoplasmic
reticulum (ER) dilation was seen in Tubb1/ compared to wild-
type thyrocytes (Fig 5C), indicating ER stress, which was confirmed
by the findings of increased Chop and XBPs expression by quantita-
tive PCR and of increased Chop protein levels by Western blotting
in Tubb1/ thyroids (Fig 5D). By immunohistochemistry, the ER
marker KDEL co-localized with TG in Tubb1/ and wild-type mice
but was especially abundant in disorganized areas of adult Tubb1/
thyroids (Fig 5E).
These data indicated partial thyroid tissue disorganization,
vesicle accumulation and ER stress in Tubb1/ mice.
In sum, our findings in Tubb1/ mice demonstrate a complex
mechanism of hypothyroidism involving early abnormal prolifera-
tion of progenitors, delayed thyroid migration, defective thyroid dif-
ferentiation, impaired thyroid hormone release and structural
disorganization of the thyroid tissue. The abnormal thyroid
migration may explain the thyroid phenotype found in patients
carrying TUBB1 mutations, especially those with thyroid gland
ectopia.
Analysis of platelets from patients bearing TUBB1 mutations
Until now, b1-tubulin expression had been reported only in the
megakaryocyte lineage (Patel et al, 2015). TUBB1 mutations have
been previously reported to cause macrothrombocytopaenia
(Kunishima et al, 2009, 2014; Fiore et al, 2017). We therefore
studied the platelets of the above-described patients with TUBB1
mutations and thyroid gland abnormalities.
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Haematological parameters (Fig 1)
Thrombocytopaenia was a feature in patients with TUBB1 mutations
studied by other groups (Kunishima et al, 2009, 2014; Fiore et al,
2017). However, when we used an automated haematology analyser
to measure the platelet count and mean platelet volume (MPV) in
our seven patients, we consistently found normal platelet counts. In
contrast, MPV was above the normal range in P1 and near the upper
limit of normal in P4 and P7. A blood smear analysis (Fig 6A)
demonstrated variations in platelet size with the presence of macro-
platelets. Moreover, parents I.1 and I.2 of family F1 had MPV values
at the top of the normal range (10.2 and 11.3 fl, respectively;
normal, 7.5–11.2 fl) with many macroplatelets. Electron microscopy
confirmed the large platelet size (Fig 6B).
The increased platelet size could be related to defects in their
biogenesis. To study this, we cultured megakaryocytes from patients
P1 and P4 from peripheral blood progenitors and analysed proplatelet
formation (Fig 6C). Interestingly, shaft thickness and coiled element
diameter of the future platelets were significantly increased compared
to controls, indicating that the TUBB1 mutations affected proplatelet
formation and platelet size.
A
B
D
C
Figure 4. Tubb1/ mice have abnormal thyroid development.
A Thyroid morphology was investigated using Nkx2-1 staining at E9.5 and E11.5 (sagittal sections) and at E13.5, E15.5 and E17.5 (transverse sections) in wild-type (wt)
and Tubb1/ littermates. Nkx2-1 was used as a marker of early thyrocyte progenitors and differentiated thyrocytes. Delays in thyroid migration and in fusion of the
median anlage to the ultimobranchial bodies were observed at E11.5 and E13.5 (arrow), respectively, in Tubb1/ mice. At E11.5, stained migrating thyroid cells were
visible along the tract only in Tubb1/ littermates (arrow). At E17.5, a pyramidal lobe was visible in Tubb1/ littermates (arrow). tr: trachea; ub: ultimobranchial
body. Scale bar: 50 lm.
B Total thyroid surface area (lm2) was quantified using Nkx2-1 staining at each embryonic stage. Top: thyroid surface area normalized for weight of each embryo. Four
mice were analysed per genotype at E9.5 and five mice at E11.5. Bottom: thyroid surface area in lm2. Four mice were analysed per genotype at E9.5, five at E11.5, six
at E13.5, four at E15.5 and three at E17.5. Right: proliferation ratio calculated as the proportion of Nkx2-1-positive cells labelled with Ki67 at E9.5 in wt and Tubb1/
thyroid anlages. Four mice were analysed for wild-type genotype and five for Tubb1/. ma: median anlage. Note that the thyroid ma is larger and the proliferation
ratio higher at E.9.5 in Tubb1/ mice, whereas from E13.5 onwards the Tubb1/ thyroids were hypoplastic. Wt in black, KO, Tubb1/ in grey.
C Thyroid marker expression by quantitative PCR in thyroid tissue at E15.5 and E17.5 in Tubb1/ versus wt mice normalized for peptidylprolyl isomerase A. Note the decreases
in thyroid differentiation markers at E15.5 and E17.5 and also in thyroid transcription factors at E17.5. Four mice were analysed per genotype at E15.5 and three at E17.5.
D Staining of Nkx2-1 and T4 at E17.5 and surface area quantification demonstrating T4 retention in Tubb1/ versus wt thyroids. The data are the percentage of T4 or
calcitonin (CT) surface area versus total thyroid area (estimated from the Nkx2-1-stained surface area). Three mice were analysed per genotype. Scale bar: 50 lm.
Data information: Results are reported as mean  SEM. Student’s t-test, *P < 0.05, **P < 0.01 and ***P < 0.001.
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Functional analysis of human platelets
We first quantified b1-tubulin expression in the platelets of our
patients and found significant decreases (P < 0.001) of 45.0  3.7%
and 36.5  3.4% in P1 and P3 (F1), respectively; 45.0  3.8% in
P4 (F2); and 29.1  3.3% and 30.6  6.2% in P6 and P7 (F3),
respectively. Expression of a-tubulin was normal (Fig 7A). The b1-
tubulin antibody used in our study detects only the C-terminal part
of the protein. Consequently, in the patients of families F2 and F3,
whose mutations created premature stop codons, only the wild-type
protein was detected. In the F1 patients, who were homozygous for
the mutation, the results suggested either diminished protein expres-
sion or protein instability.
Then, to investigate whether the TUBB1 mutations affected
platelet function, we assessed platelet activation by flow cytometry
using a specific monoclonal antibody (PAC1), which recognized the
active conformation of the integrin aIIbb3, a platelet activation
marker. PAC1 binding was significantly increased in P1 and P3,
indicating abnormal platelet activation, whereas in P6 and P7 (F3)
aIIbb3 activations were comparable to those in controls (Fig 7B). We
were unable to evaluate P4 (F2).
A
D
E
B C
Figure 5. Tubb1/ mice have altered thyroid function with impaired hormone secretion.
A Serum TSH and T4 levels in 3-month-old Tubb1/ and wild-type mice. Numbers of animals tested were 10 wild-type males and 14 Tubb1/ males for TSH and for
14 wild-type and 22 Tubb1/males for T4. Tubb1/ mice had hypothyroidism with elevated TSH and decreased T4 versus wild-type mice.
B Nkx2-1 (in brown) immunostaining of adult thyroid tissue. Note the disorganization of the thyroid tissue in Tubb1/ versus wild-type mice.
C Ultrastructural alterations shown by electron microscopy in wild-type and Tubb1/ thyroid tissues. In Tubb1/ tissues, note the disorganization of secretion vesicles
(white asterisks) and rods of identical density to secretion vesicles (white arrow). The ER is considerably dilated in Tubb1/ thyrocytes. Representative views. Scale
bars at the bottom left for each view. Co: colloid.
D ER stress in Tubb1/ thyroid tissue. Top: Chop and XBPs expression by quantitative PCR in adults, normalized to peptidylprolyl isomerase A. Experiments with four
tissues per stage for each genotype; wt in black and Tubb1/ in grey. Bottom: Chop and Actin protein expression by Western blotting in three representative wild-
type and Tubb1/ mice. The Chop band quantification normalized for Actin confirms the increased Chop expression demonstrated by quantitative PCR in Tubb1/
versus wild-type thyroids. All lanes are from the same blot, which was cut where indicated.
E Co-immunostaining of endoplasmic reticulum (ER) marker (KDEL, in red), thyroglobulin (Tg in green) and both merged (from left to right) in adult thyroid tissue. Note
the thyrocyte disorganization in Tubb1/ mice.
Data information: Results are reported as mean  SEM. Student’s t-test, *P < 0.05, **P < 0.01.
Source data are available online for this figure.
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Finally, we investigated the aggregations of washed platelets
upon activation by ADP or collagen, two key platelet agonists
(Fig 7C). Aggregation in response to ADP was normal in P6 and P7
(F3) but increased in P1 and P3 (F1) and in P4 (F2) compared to
controls. Similarly, collagen-induced platelet aggregation was
normal in P6 and P7 but was increased in P1 and P4, even with low
doses. These abnormal platelet aggregations were not related to
hypothyroidism or patient’s treatment by L-thyroxine, since they
were not found in three patients with thyroid ectopy not harbouring
TUBB1 mutations and under the same treatment (Appendix Fig S5).
Moreover, it should be noted that these results were confirmed by
at least three independent investigations for P1 and P3 and two for
P6. The other patients were studied once. None of the nine controls
exhibited similar hyperaggregation profile.
In summary, these results indicate that p.P160L (F1), p.Y106X
(F2) and c.35delG (F3) TUBB1 mutations affect b1-tubulin expres-
sion in platelets and result in abnormally large platelet size, probably
as a consequence of proplatelet abnormal formation. Moreover, the
p.P160L mutation induces significant platelet activation in resting
condition and hyperaggregation in response to agonists, whereas the
c.35delG mutation does not seem to affect platelet function.
Discussion
We identified three TUBB1 mutations in patients with TD and
macroplatelets. In a consanguineous family (F1), two females with
CH and thyroid gland ectopia had the same homozygous TUBB1
mutation, and their brother had thyroid gland hypoplasia with
normal function. Of 270 patients with CH and TD, two probands
from unrelated families had heterozygous TUBB1 mutations. All
patients with heterozygous or homozygous TUBB1 mutations had
TD and macroplatelets. Thyroid gland ectopia was the most
common form of TD, but mild thyroid asymmetry, thyroid hypo-
plasia and hemithyroid were also seen.
This is the first time that CH with TD was associated with macro-
platelets, and we demonstrate in our study that TUBB1 mutations
are the common cause. b1-tubulin expression has heretofore been
A C
B
Figure 6. TUBB1 mutations induce abnormal platelet formation or macroplatelets.
A Representative blood smears of patients with TUBB1 mutations (P1 and P3 homozygous for p.P160L, P4 heterozygous for p.Y106X, and P6 and P7 heterozygous for
c.35delG) after May–Grünwald–Giemsa staining. Variable platelet size in patients was observed with all three mutations with the presence of macroplatelets (arrows).
B Transmission electron microscopy (TEM) analysis of platelet ultrastructure in the patients. The results confirm the abnormal platelet morphology.
C Representative images of proplatelet formation in P1 and P4. Cultured control and patient megakaryocytes (MKs) after thrombopoietin-induced differentiation were
spread over a BSA-coated coverslip on day 10. On day 13 or 14, MKs were fixed (4% paraformaldehyde) and proplatelet structure was observed after b-tubulin
staining. Scale bars: 20 lm. Only P1 and P4 could be studied. The graphs show the mean  SEM of the shaft thickness of proplatelet extensions (left) and the
diameter of coiled elements (right) of the future proplatelets, both of which were significantly increased in the patients, indicating that the TUBB1 mutations
(homozygous p.P160L and heterozygous p.Y106X) affected proplatelet morphology. Statistical significance was determined by one-way ANOVA, followed by Dunnett’s
multiple comparisons test (*P < 0.05, ***P < 0.001; 20–60 MKs were analysed/patient).
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described as confined to megakaryocytes and platelets. Our findings
demonstrate that b1-tubulin is also expressed in developing and
adult thyroid tissue. Furthermore, CH and TD were found in humans
with TUBB1 mutations and in Tubb1/ mice. These data indicate
that normal thyroid development and function require b1-tubulin
incorporation into the microtubule network. Furthermore, our
patients with TUBB1 mutations had normal platelet counts but
abnormal platelet morphology, and two of the three mutations
(p.P160L and p.Y106X) were associated with abnormal platelet func-
tion. In contrast, in previous studies, humans with TUBB1 mutations
and Tubb1/ mice had macrothrombocytopaenia but no reported
thyroid disorders (Kunishima et al, 2009, 2014; Fiore et al, 2017).
The previously reported TUBB1 mutations affect the intermediate
or C-terminal domain of b1-tubulin, whereas the three novel muta-
tions described here modify the N-terminal domain. However,
during the drafting of this work, Bastida et al (2018) published a
genetic analysis of a cohort of patients with inherited platelet disor-
ders where they identified four novel TUBB1 mutations: two in the
C-terminal domain and two in the N-terminal domain, including the
same mutation that we described here for family F3, c.35delG. In
their study, the patient with the c.35delG mutation had a thrombocy-
topaenia, which differs from the normal platelet count of our family
F3. This discrepancy could be explained by another factor, different
from the TUBB1 mutation, which could induce thrombocytopaenia.
Two of our described mutations gave stop codon earlier but not
the p.P160L mutation. The p.P160L protein expression was decreased
in the platelets of patients, but the hypothesis of the protein instabil-
ity was not conclusive in vitro experiments (data not shown). Others
mechanisms should be considered. Strikingly, all three mutations are
loss-of-function mutations: two of the mutations lead to truncated
b1-tubulin, which cannot form functional a/b-tubulin dimers and
thus cannot be incorporated into microtubules. The third is a
missense mutation (P160L), which, despite expressing full-length b-
tubulin, still does not allow the formation of functional a/b-tubulin
dimers to be integrated into the microtubules network. Hence, the
three TUBB1 mutations were deleterious for the b1-tubulin function,
which is confirmed on the functional level, as their phenotypes are
similar to those of the Tubb1/ mouse. Consequently, Tubb1/
mice emerged as a useful tool for studying the impact of impaired b1-
tubulin function on the thyroid gland. Considering the hypothy-
roidism phenotype present only in Nkx2-1/ or Pax8/ or double
Nkx2-1+/Pax8+/ mice, we decided to study directly the knock-out
mice (Kimura et al, 1996; Mansouri et al, 1998; Amendola et al,
2005). Haploinsufficiency of one of these critical genes for thyroid
development causes hypothyroidism in humans, whereas in mice,
the homozygous deletion leads to thyroid phenotype.
Our experiments in Tubb1/ mice provided the first evidence of
a role for b1-tubulin in TD and hypothyroidism. The thyroid glands
A B
C
Figure 7. TUBB1 mutations alter protein expression in platelets and platelet functions.
A Relative expression of a-tubulin and b1-tubulin in platelets from P1 and P3 (homozygous p.P160L), P4 (heterozygous p.Y106X), and P6 and P7 (heterozygous c.35delG)
was quantified by Western blotting using specific antibodies against a-tubulin or b1-tubulin. With both mutations, a-tubulin expression was normal but b1-tubulin
expression was significantly decreased. The b1-tubulin antibody recognizes C-terminal domain.
B aIIbb3 integrin activation was evaluated by flow cytometry (% of positive platelets and mean fluorescence intensity) in whole blood from P1 and P3 (homozygous
p.P160L) and from P6 and P7 (heterozygous c.35delG); P4 could not be studied. While no aIIbb3 integrin activations were detected in P6 and P7 (family 3), P1 and P3
(family 1) exhibited a significant increase in aIIbb3 activation, indicating basal platelet activation.
C Aggregation of washed platelets induced by ADP (5 or 10 lM) or collagen (0.6, 0.8 or 2 lg/ml) was evaluated in at least one member of each family. Patients from
families 1 and 2 had increased platelet aggregation in response to low doses of agonist versus controls, suggesting that TUBB1 affected by homozygous p.P160L and
heterozygous p.Y106X mutations affected platelet function. Platelet aggregation to both agonists was normal in both patients from family 3 (heterozygous c.35delG).
Data information: Results are reported as mean  SEM. Family F1, n = 3 independent experiments; Family F2, n = 1 experiment; Family F3, n = 2 independent
experiments. Statistical significance was determined by one-way ANOVA, followed by Dunnett’s multiple comparisons test (*P < 0.05, **P < 0.01, ***P < 0.001, nd:
statistical significance not determined because n ≤ 2).
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of Tubb1/mice exhibited abnormal proliferation at E9.5, default of
migration at E11.5 and E13.5, and hormone secretion failure at E17.5
and adulthood. All these mechanisms require normal microtubule
organization and function. The idea that microtubule functions are
fine-tuned and thus adapted to specific cellular role by the expression
of specific tubulin isotypes is an emerging concept known as the
“tubulin code” (Janke, 2014). Tubulin mutations have been more
and more linked to different human disorders, in particular to neuro-
logical disorders (Chakraborti et al, 2016). Microtubules are essential
for mitosis to unfold normally (Prosser & Pelletier, 2017). Here, we
show that invalidation of b-tubulin isotype Tubb1 perturbs mitosis of
progenitors at E9.5, thus inducing hyperproliferation. Mitotic pheno-
types have already described during neuronal development in mice
with loss of another b-tubulin isotype, Tubb5 (Breuss et al, 2012).
Moreover, normal thyroid development requires that progenitor
proliferation occurs during a specific time window (Nilsson &
Fagman, 2017). Early proliferation at E9.5, as described by our group
in Hes1/ mice (Carre et al, 2011), results in abnormal thyroid
development, probably via impairment of the pool of progenitors
dedicated to thyroid development. Furthermore, microtubules are
required for cell orientation during migration (Ladoux et al, 2016).
Our data in the Tubb1/ mice show a delay of thyroid progenitors
cell migration during thyroid development, which again is mirrored
by Tubb5/ that show impaired neuronal migration (Breuss et al,
2012). In our patients with TUBB1 mutations, thyroid gland ectopia
was the most common form of TD (4/7 patients), further supporting
a role for b1-tubulin in thyroid gland migration. The delay of thyroid
bud migration could be reminiscent of the dual ectopy seen in 9% of
CH due to ectopy (Wildi-Runge et al, 2012). Finally, endosome/lyso-
some trafficking is taking place on microtubules (Huotari & Helenius,
2011; Raiborg et al, 2015; Bonifacino & Neefjes, 2017). Endosome-to-
lysosome transport of thyroid hormones via a vesicular transport
system has been described in the thyroid gland (Rousset et al, 2015;
Carvalho & Dupuy, 2017). A proper thyroid microtubule integrity is
required for thyroid hormone secretion established by previous stud-
ies done in the 1970s (Ne`ve et al, 1972; Wolff & Bhattacharyya,
1975). While so far nothing is known on the precise role of tubulin
isotypes and microtubules organization in trafficking of thyroid
hormone vesicles, there is strong evidence that transport along
microtubules is affected by the tubulin code (Nirschl et al, 2016).
Our data are the first to demonstrate that a specific tubulin isotype,
b1-tubulin, is required for proper vesicle trafficking and thyroid
hormone release into the bloodstream, and they extend our knowl-
edge about the association between microtubules and secretion vesi-
cles in the thyroid gland. Furthermore, we have shown an increased
expression of ER stress markers in the Tubb1/ thyroid. Previous
studies demonstrated ER stress with activation of the unfolded
protein response in association with reduced thyroglobulin (TG)
synthesis and TG accumulation within the ER (Gaide Chevronnay
et al, 2015; Di Jeso & Arvan, 2016). We can conclude that thyroid
dysgenesis is a feature in TUBB1 mutation carriers and in Tubb1/
mice. The data on variable degrees of hypothyroidism in humans
corroborate with the thyroid function data in mice as the variable
TSH values have been found.
b1-tubulin is the most divergent isotype of tubulin, and its incor-
poration into microtubules is expected to change the properties of
these filaments. Losing b1-tubulin thus certainly alters microtubule
properties, and our data provide strong evidence that these
particular properties are necessary for adequate thyroid develop-
ment and function.
Our patients with TUBB1 mutations had macroplatelets. This
abnormal platelet size is further evidence that TUBB1 mutations
adversely affect platelet morphology probably as a consequence of
proplatelets formation. In these previously described mutations,
only the p.R318W mutation has been investigated in platelet aggre-
gations and it did not induce defect of platelet function (Kunishima
et al, 2009). For the other mutations (Kunishima et al, 2014; John-
son et al, 2016; Fiore et al, 2017; Bastida et al, 2018), no bleeding
tendency have been reported. Here, our patients with p.P160L and
p.Y106X mutations exhibited an unexpected increase in platelet
functions, raising the question whether these platelet function
abnormalities result in clinical symptoms such as thrombosis
requires evaluation, particularly in older patients who may be at
increased risk. Thyroid dysfunction can affect the haemostatic
balance (Squizzato et al, 2007; Kyriakakis et al, 2016), with clinical
effects that vary across thyroid disorders (Franchini et al, 2010).
Moreover, MPV correlated positively with the TSH level (Kim et al,
2013). A TUBB1 mutation screening study in patients with hypothy-
roidism and altered MPV and/or a history of thrombotic disease
would be of great interest. Therefore, patients bearing a TUBB1
mutation with cardiovascular risk factors could be monitored and
the question arises whether antiplatelet drugs might be effective as
prophylaxis (Kuhli-Hattenbach et al, 2017). Conversely, thyroid
function and morphology assessment could be suggested in patients
with congenital macrothrombocytopaenia.
The c.35delG mutation in P6 and P7 did not cause hyperaggrega-
tion. The patients with the c.35delG mutation had the same thyroid
phenotype as other families with other mutations. At least one
patient per family had thyroid gland ectopia with CH. Neither
thyroid nor platelet phenotype severity correlated with the type of
mutation. Further investigations are needed to elucidate the dif-
ference between the effects of c.35delG and p.P160L/p.Y106X on
platelet function.
The common feature in TUBB1mutation carriers is thyroid dysge-
nesis and abnormal platelet morphology. TUBB1 mutations consti-
tute a model of dominant inheritance of CH with TD. Most known
mutations responsible for TD and previously described TUBB1
mutations causing macrothrombocytopaenia are also dominant
(Kunishima et al, 2009, 2014; Guillot et al, 2010; Ramos et al, 2014;
Carre´ et al, 2017; Fiore et al, 2017). Our data indicate high pene-
trance for platelet alterations and incomplete penetrance with vari-
able expressivity for TD, ranging from TD without CH to TD with CH
and leading to variable types of TD (ectopia, hypoplasia, hemithy-
roid or asymmetric thyroid gland). No patient had athyreosis.
Indeed, in the described familial pedigrees, some carriers have mild or
no thyroid phenotype, suggesting that the TUBB1 germline mutation
may be necessary to be affected by CHTD but it is probably not suffi-
cient to display the phenotype. A second hit (such as a somatic muta-
tion in the thyroid or an epigenetic defect) could be the additional
prerequisite to express the disease. Furthermore, the hypothesis of
random autosomal monoallelic expression in the thyroid could
explain the difference in intrafamilial phenotypic variability in F3.
These hypotheses are already documented in the literature for TD
(Deladoe¨y et al, 2007; Magne et al, 2016). Finally, the genetics of TD
remains complex with mutations in more than nine known genes and
both classical and complex modes of inheritance, such as a suggested
ª 2018 The Authors EMBO Molecular Medicine 10: e9569 | 2018 11 of 18
Athanasia Stoupa et al TUBB1 mutations in thyroid dysgenesis EMBO Molecular Medicine
oligogenic model by Persani et al (de Filippis et al, 2017). The same
genetic pattern of inheritance is also observed in other endocrine-
related disorders such as congenital hypogonadotropic hypogonadism
(Boehm et al, 2015) or in the more complicated genetic model of
Bardet–Biedl syndrome (Muller et al, 2010).
TUBB1 mutations were found in only 1.1% of our cohort with
CH and TD patients. The Burden test showed enrichment in rare
TUBB1 variants carriers in the cohort versus controls. Our data
increment the number of predisposing genes for thyroid dysgenesis
but with a novel phenotype associating platelet disorder.
Taken together, our data indicate heretofore unsuspected roles
for a specific isotype of b-tubulin, Tubb1, in thyroid development
and function, while also confirming its importance for microtubule
integrity and platelet function. Loss-of-function of TUBB1 mutations
impairs b1-tubulin incorporation into microtubules. Our results con-
firm that normal thyroid-cell proliferation and thyroid migration are
essential to thyroid gland development. Thyroid hormone secretion
requires b1-tubulin incorporation into the microtubules, suggesting
a specific function of this tubulin isotype in intracellular transport of
vesicles. Thus, our work provides novel insights into the role of the
Tubb1 isotype in thyroid physiopathology and in platelet function
and therefore expands the spectrum of the rare paediatric diseases
related to tubulin mutations and microtubule dysfunction.
Materials and Methods
Patients
We have a large study cohort of patients with congenital hypothy-
roidism due to TD. Patients have been diagnosed with primary CH
during the first days after birth by the systematic neonatal screening in
France (TSH > 15 mU/l). Diagnosis of CH was confirmed with a
control blood sample during the first weeks of life and imaging tests
(thyroid ultrasonography and thyroid scintigraphy). A consanguineous
family in which two children had TD and CH and another had small
thyroid gland with normal thyroid function was initially studied.
Subsequently, genetic testing was performed in 270 patients (184 girls
and 86 boys) with CH and TD (ectopic thyroid gland, n = 167; athyreo-
sis, n = 77; hemithyroid n = 20; and thyroid hypoplasia, n = 6). This
study was approved by the review board (Ethics Committee, Ile de
France, Paris, France: P11012-IDRCB 2012-A00797-36). The written
informed consent forms were collected, and the experiments
conformed to the principles set out in the WMA Declaration of Helsinki
and the Department of Health and Human Services Belmont Report.
Detection of mutations in humans
Genomic DNA was isolated from whole blood. Exome capture and
sequencing were performed at the genomics platform of the
IMAGINE Institute. WES libraries were prepared from 3 lg genomic
DNA per individual, which was sheared by ultrasonication (Covaris
S220 Ultrasonicator, Woburn, MA, USA). Exome capture was
performed using the SureSelect Human All Exon V6 Kit (Agilent
Technologies, Santa Clara, CA, USA). The resulting libraries were
sequenced on a HiSeq 2500 HT device (Illumina, San Diego, CA,
USA) according to the manufacturer’s recommendations. Paired-end
(2 × 130) 76-bp reads were generated and mapped on the human
reference genome. More than 97% of the exome was covered at
least 30 times. Raw data were analysed as described (Gordon et al,
2013), using an in-house software system (Polyquery). The variant
prioritization strategy was as follows: (i) selection of functional
(protein-altering) variants (removal of intergenic and 30/50 UTR vari-
ants, non-splice-related intronic variants and synonymous variants);
(ii) variants with a frequency below 1% in public databases
(dbSNP, 1000 Genomes, EVS, ExAC; release date, January 2018);
and (iii) variants previously identified in fewer than five individuals
contributing 11,811 in-house exomes (Appendix Fig S1).
The HypothySeq NGS Panel included 78 genes known to be asso-
ciated with CH (TD; dyshormonogenesis; defects in thyroid hormone
(TH) transport proteins; and inborn errors in TH membrane trans-
port, metabolism or action) and candidate genes validated in animal
models (mouse and zebrafish knock-out models) or by microarray
assays but not yet validated in humans. This panel was previously
validated using controls including samples from positive controls
with known thyroid disease-causing mutations, to assess sensitivity
(false-negative rate); and from healthy individuals screened by WES
for another research study, to test specificity (false-positive rate).
Genomic DNA libraries were created using SureSelectXT Target
Enrichment Reagent Kit (Agilent Technologies) and subjected to
custom-targeted DNA panel enrichment. In the 78 genes associated
with CH, 1,006 regions of interest were captured by the correspond-
ing 120-bp cRNA baits, using SureDesign software (Agilent Tech-
nologies; Homo sapiens, hg19, GRCh37, February 2009). The
233,103-bp targeted DNA regions (protein-coding exons of the main
isoform and supplementary coding exons of each gene, including 25-
bp flanking intronic sequences) were sequenced on Illumina HiSeq
2500 (Illumina). This step generated 2 × 130 paired-end reads.
Bioinformatic analyses included alignment against the reference
genome, variant calling and annotation, and copy number variation
(CNV) detection. All data were integrated in the dedicated interface
Polydiag developed by the bioinformatics platform at the IMAGINE
Institute to check coverage of the targeted regions, to sort and filter
the called variants by impact and frequency, and to identify relevant
candidate mutations and/or CNVs for molecular diagnosis.
Sanger sequencing was performed to validate and segregate the
identified TUBB1 (NM_030773) variants (3500xL Genetic Analyzer,
Thermo Fisher Scientific, Waltham, MA, USA) with listed primers in
Table EV2.
Burden test
Rare variant burden testing was performed for the TUBB1 gene using
the CAST collapsing method (Morgenthaler & Thilly, 2007) in 270
patients with TD, including 193 with ectopia, hemithyroid or hypo-
plasia and 77 with athyreosis. Contrary to a single-variant associa-
tion test, variants of the same gene were aggregated and considered
as a whole. For each individual, the presence or absence of variants
in the gene was noted. The aim of the method was then to count and
compare the number of individuals carrying at least one potentially
deleterious variant in the TUBB1 gene, in the two groups of individu-
als. To do so, a likelihood ratio test was performed to compare the
TD patients with 406 Caucasian controls from the 1,000 Genomes
project phase 3 (The 1000 Genomes Project Consortium, 2015).
Disruptive in-frame, frameshift, missense, splice-acceptor, splice-
donor, start-lost, stop-gained or stop-lost variants were considered
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deleterious. All deleterious variants with a minor allele frequency
< 1% in the ExAC database r0.2 were included in the analysis. We
first studied all 270 TD patients then only the 193 TD patients with-
out athyreosis group.
Human thyroid tissue samples
After approval by our institutional review board of the experimental
design and protocols, embryonic thyroid tissue was obtained from
products of elective termination of pregnancy and adult thyroid
tissues from patients undergoing thyroid surgery.
Animals
Tubb1/ mice were previously generated by replacing exons 3 and
4, encoding amino acids 56–451, with a neomycin-resistance gene
cassette as previously described (Schwer et al, 2001). Tubb1+/
mice on a mixed 129/Sv-BALB/c background were interbred with
C57BL/6J mice over ten generations to generate homozygous null
mutants (Tubb1/) with the C57BL/6J background (B6.CG-b1tubu-
linTM). All experiments were conducted in accordance with French
regulations and were approved by the Strasbourg Regional Ethics
Committee for animal experimentation (C.R.E.M.E.A.S., CEEA 35).
Animals were housed in a temperature-controlled room on a 12-h
light/12-h dark cycle and had free access to food and water. All adult
mice were male. Thyroids at different embryonic stages from E13.5
to E17.5 and adult thyroids at 3 months of age were obtained from
wild-type and Tubb1/ mice and microdissected as described previ-
ously (Carre et al, 2011).
Assays on mouse serum samples
Aortic blood samples were collected from 3-month-old wild-type
and Tubb1/ mice. Radioimmunoassays were used to measure
serum TSH and serum total T4 after iodothyronine extraction (Dr. S.
Refetoff, Chicago, IL, USA) as previously described (Pohlenz et al,
1999).
Flow cytometry of mouse thyroid cells
Mouse thyroid tissue from E17.5 embryos (15 pooled thyroids per
sample) and adults (four thyroids per sample) were microdissected,
cleansed of fat and connective tissue, and placed in ice-cold phos-
phate-buffered saline (PBS) containing 2% foetal calf serum (FCS).
Cells were prepared and sorted by flow cytometry as previously
described (Gawade et al, 2016). Briefly, single-cell suspensions were
obtained by enzymatic digestion with 1 mg/ml collagenase/dispase
and 2 lg/ml DNase I (Roche Diagnostics, Basel, Switzerland) at
37°C for 20 min. The cells were then centrifuged with PBS contain-
ing 2% FCS and stained with cell surface markers for 20 min.
Finally, the cells were acquired on a BD FACSAria II flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA). The following mono-
clonal antibodies were used: EpCAM/CD326 (1:1,000, clone G8.8,
# 118216), PDGFRa/CD140a (1:400, APA5, # 135906), CD45 (1:200,
clone 30-F11, # 103128) and Pecam/CD31 (1:400, clone 390,
# 102406) from BioLegend (San Diego, CA, USA); and CD41 (1:50,
clone MWReg30, # 553848, Becton Dickinson). The secondary anti-
body was goat anti-rabbit A647 from Life Technologies (1:2,000;
Carlsbad, CA, USA). Each pool of sorted cells was collected in RLT
buffer from the Qiagen RNeasy MicroKit (Qiagen, Valencia, CA,
USA) for RNA extraction experiments.
RNA extraction and quantitative RT–PCR
The thyroids were microdissected and immediately snap-frozen and
stored at 80°C. Total RNA of sorted cells or thyroid tissue was
isolated using the Qiagen RNeasy MicroKit or MiniKit (Qiagen). The
Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific)
was used for reverse transcription of 250 ng of each RNA sample.
The synthesized cDNA was diluted to 1/20, and 5 ll was used for
each PCR. Each reaction consisted of TaqMan Universal PCR Master
Mix or SybrGreen PCR Master Mix (Thermo Fisher Scientific) and
primers. Peptidylprolyl isomerase A served as an endogenous
control. Real-time PCR was performed using the QuantStudio 3
Real-Time PCR System (Thermo Fisher Scientific). The data were
analysed using the comparative cycle threshold method and
reported as the fold change in gene expression, normalized for a
calibrator of value 1. Primers sequences for human TUBB1 were as
follows: Forward GGGACGATGGACAGCATTCGAT and Reverse
ACCTCTAGGACATTCTCGATCAGC. Primers sequences for mice a
and b-tubulin are listed in Appendix Fig S4B.
Immunohistochemistry and quantification
Human or mouse tissues were fixed by immersion in 3.7% buffered
formalin then embedded in paraffin. Subsequently, 4-lm-thick
sections were mounted on StarFrost adhesive slides (Knittel Glaser,
Braunschweig, Germany) and processed for immunohistochemistry,
as previously described (Carre et al, 2011). The primary antibodies
were used at the following dilutions: rabbit antibody to human or
mouse b1-tubulin, 1:1,000 (donated by Franc¸ois Lanza), rabbit anti-
Ecadherin, 1:100 (# 610682, Becton Dickinson), mouse anti-TG,
1:100 (# M0781, DakoCytomation, Glostrup, Denmark), rabbit anti-
Nkx2-1, 1:2,500 (#PA0100, Biopat, Italy), mouse anti-T4, 1:10,000
(clone BGN/0980/322, # 8959-9831, AbD Serotec, Raleigh, NC,
USA), rabbit anti-calcitonin, 1:400 (# A0576, DakoCytomation),
mouse anti-Ki67, 1:20 (# 550609, Becton Dickinson) and rabbit anti-
KDEL, 1:1,500 (# PA1-013, Thermo Fisher Scientific). The fluores-
cent secondary antibodies were Alexa Fluor 594 goat anti-rabbit and
Alexa Fluor 488 goat anti-mouse antibodies (1:400, Thermo Fisher
Scientific). The nuclei were stained using the Hoechst 33,342 fluo-
rescent stain (0.3 mg/ml; Thermo Fisher Scientific). Photographs
were taken using a fluorescence microscope (Leitz DMRB; Leica,
Wetzlar, Germany) and digitized using a chilled 3CCD camera
(C5810; Hamamatsu Photonics, Hamamatsu City, Japan).
The sections were then analysed using ImageJ 1.32s (freeware,
www.rsbweb.nih.gov/ij) as previously described (Carre et al, 2011;
Kariyawasam et al, 2015). The Nkx2-1-positive surface areas per
section allowed us to draw the total thyroid surface area in lm2.
The surface areas positive for calcitonin and T4, two markers of late
thyroid differentiation, were normalized for total thyroid surface
area. For stained surface quantification, we used one of every two
sections at E9.5 and E11.5, one of every five sections at E13.5 and
five sections per adult thyroid (3 months of age). We determined
the surface area to obtain an estimate of the total stained surface for
each thyroid and each marker. Proliferation of Nkx2-1-positive cells
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at E9.5 was estimated by counting Ki67-positive nuclei among
Nkx2-1-positive cells on every other section throughout the entire
tissue sample at E9.5. At least three thyroids were analysed per
genotype. The results are reported as mean  SEM.
For Nkx2-1 staining of adult mouse thyroid glands, the first
immunohistochemistry steps were as described above. After appli-
cation of the primary antibody, the sections were incubated with
biotinylated secondary antibody for 1 h. Immunostaining was then
performed using the Vectastain ABC Kit (Vector Laboratories,
Burlingame, CA, USA) according to the manufacturer’s instructions.
The sections were then incubated in 3,30-diaminobenzidine tetrahy-
drochloride and counterstained with hemalum–eosin.
Western blot studies of mouse thyroid tissue
Proteins prepared from mouse thyroid tissue collected in RIPA
buffer and sonicated were quantified using the BCA protein assay
(Thermo Fisher Scientific). Then, 20 lg of total protein was sepa-
rated on Bis–Tris polyacrylamide gel with a 4–12% gradient
(Thermo Fisher Scientific) and transferred onto PVDF membranes
(Thermo Fisher Scientific). The membranes were incubated with the
primary antibodies mouse anti-Chop (1:1,000, # 2895, Cell Signaling
Technology, Danvers, MA, USA) or rabbit anti-Actin (1:2,000,
# A5441, Sigma-Aldrich) antibodies, followed by horseradish peroxi-
dase-conjugated goat anti-mouse or anti-rabbit antibodies. Binding
of secondary antibodies was revealed using the Amersham ECL
Prime Detection Reagent Kit (GE Healthcare, Chicago, IL, USA). The
protein bands on the membranes were scanned with the Image-
Quant LAS 4000 Station (GE Healthcare) and then analysed using
ImageJ 1.32s to determine the protein levels, with Actin protein
serving as an internal control.
Molecular modelling of the P160L mutated protein
The wild-type human TUBB1 sequence (accession number:
Q9H4B7) was downloaded from the UniProt database, and the
P160L mutation introduced into it. Both the wild-type and mutant
TUBB1 sequences were modelled using Modeller 9.18 software (Sali
& Blundell, 1993) with PDB 4I4T chain B as the template (Prota
et al, 2013). The models were analysed using PyMOL visualization
software (DeLano, 2002).
Electron microscopy
Samples were fixed for 1 h in 3% glutaraldehyde in PBS buffer,
washed and embedded in Epon. 90-nm sections were collected on
nickel grids and contrasted with uranyl acetate and lead citrate.
Acquisitions were performed with a Gatan Orius 1000 CCD Camera
(Gatan, Pleasanton, CA, USA) on a JEOL 1011 transmission electron
microscope (JEOL, Tokyo, Japan).
Plasmids, cell cultures, transfection and immunofluorescence
We used the phumanTUBB1-tagged Myc vector described by
Kunishima et al (2009). Mutant P160L-TUBB1 was generated using a
PCR-based site-directed mutagenesis method as described previ-
ously, using the Stratagene QuikchangeVR Kit (Agilent Technologies;
Carre´ et al, 2007). Nthy (Nthy-ori 3.1; given by Corinne Dupuy)
immortalized human thyroid-cell lines were cultured as previously
described and used from passage 12 (Lemoine et al, 1989). The Nthy
cells were plated at 0.4 × 105/well on poly-L-lysine-coated slides in
12-well plates 24 h before transfection then transfected with 500 ng
of vectors containing wild-type or P160L mutant TUBB1 using Xtre-
meGENE-HP-DNA, as recommended by the manufacturer (Roche
Applied Science, Penzberg, Germany). After 24 h, cells were used for
immunofluorescence as already described (Bourg et al, 2015). The
cells were washed with pre-warmed PHEM buffer; fixed with 4%
PFA, 0.2% glutaraldehyde and 0.5% Triton; and permeabilized with
PBS-Triton 0.1%. Immunostaining was performed with rabbit anti-
Myc antibody (# 2272, 1:500, Cell Signaling Technology) and mouse
anti-a-tubulin (DM1A, # T9026, 1:1,000, Sigma-Aldrich, Saint-Louis,
MI, USA) then with Alexa Fluor 647 goat anti-rabbit and Alexa Fluor
555 goat anti-mouse antibodies (1:400, Thermo Fisher Scientific).
Human megakaryocytes and proplatelet formation
CD34+ cells were isolated from peripheral blood using an immuno-
magnetic technique according to the manufacturer’s instructions
(#130-046-70, Miltenyi Biotec, Bergisch Gladbach, Germany).
Briefly, 100 ll FcR blocking reagent and 100 ll CD34 MicroBeads
were incubated with 108 cells. The remaining population was
cultured at 37°C in 5% CO2 in Iscove’s modified Dulbecco’s medium
(IMDM; Thermo Fisher Scientific) supplemented with 15% BIT 9500
serum substitute (Stemcell Technologies, Vancouver, Canada), a-
monothioglycerol (Sigma-Aldrich) and liposomes (phosphatidyl-
choline, cholesterol and oleic acid; all from Sigma-Aldrich), in the
presence of human recombinant stem cell factor (SCF, 20 ng/ml,
Miltenyi Biotec) and human thrombopoeitin (50 nM, Miltenyi
Biotec) added once on day 0 to the culture medium, followed by
20 nM thrombopoeitin alone on day 6 with no further SCF addition.
For proplatelet formation assays, megakaryocytes were plated on a
BSA-coated surface (chamber slide, Ibidi, Martinsried, Germany) on
day 10. On day 13 or 14, the megakaryocytes were fixed using 4%
paraformaldehyde and stained for b-tubulin.
Preparation of washed platelets
To obtain human platelets, venous blood from healthy donors or
patients was collected in 10% ACD/A buffer (75 mM sodium citrate,
44 mM citric acid, 136 mM dextrose, pH 4.5). Platelets were washed
as previously described (Adam et al, 2003) in the presence of
apyrase (100 mU/ml) and prostaglandin E1 (1 lM) to minimize
platelet activation. Platelet counts in patients and controls were
adjusted to similar levels (3 × 108 platelets/ml) in Tyrode’s buffer
(137 mM NaCl, 2 mM KCl, 0.3 mM NaH2PO4, 1 mM MgCl2,
5.5 mM glucose, 5 mM N-2-hydroxyethylpiperazine-N0-2-ethanesul-
fonic acid, 12 mM NaHCO3 and 2 mM CaCl2, pH 7.3).
Platelet aggregation
Platelet aggregation was monitored by measuring light transmission
through a stirred suspension of washed platelets (3 × 108/ml) at
37°C using a Chrono-Log Aggregometer (Chrono-Log Corporation,
Havertown, PA, USA), as previously described (Adam et al, 2010).
Platelet aggregation was triggered by ADP and type I collagen
(Chrono-log Corp.).
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Flow cytometry of human platelets
Whole blood from healthy donors or patients was diluted in PBS to
obtain a platelet concentration of 2.5 × 107/ml. Diluted whole blood
was then incubated with phycoerythrin (PE)-anti-human CD62P
(clone AK-4; eBioscience, Thermo Fisher Scientific, 5 ll anti-CD62P-
PE/5 × 105 platelets) or fluorescein isothiocyanate (FITC) anti-
human-activated aIIbb3 integrin (clone PAC-1; #340507, Becton
Dickinson, 20 ll PAC-1-FITC/5 × 105 platelets) according to manu-
facturer’s instructions for 20 min at room temperature. The samples
were then analysed directly with an Accuri C6 flow cytometer
(Becton Dickinson).
Western blotting study of human platelets
Washed platelets (300 ll; 3 × 108/ml) were lysed in Laemmli
sample buffer (10 mM HEPES, 2% SDS, 10% glycerol and 5 mM
EDTA). The proteins were separated by sodium dodecyl sulphate
(SDS)-polyacrylamide gel electrophoresis and transferred to nitrocel-
lulose membranes, which were incubated with the primary antibod-
ies rabbit anti-a tubulin (1:1,000, Clone EP1332Y; Merck Millipore,
Billerica, MA, USA) or rabbit anti-b1-tubulin antibody (1:1,000,
donated by Franc¸ois Lanza). Immunoreactive bands were visualized
with enhanced chemiluminescence detection reagents (Perbio
Science, Thermo Fisher Scientific) using a G:BOX Chemi XT16
Image System and then quantified using Gene Tools version
4.03.05.0 (Syngene, Cambridge, UK).
Statistics
Sample size determination was based on previous experience with
similar studies. Results are reported as mean  SEM for the number
of experiments indicated in the figure legends. Statistical analyses
were performed using GraphPad Prism4 (GraphPad, La Jolla, CA,
USA). Data were analysed by one-way ANOVA followed by
Dunnett’s test, except for those parameters involving comparison of
only two experimental groups, in which case an unpaired Student’s
t-test was used as indicated in the figure legends. Differences were
considered significant when P < 0.05. All P-values for figures can be
found in Appendix Table S3.
Data availability
The datasets produced in this study are available in the following
database: Clinical data: ClinVar accession numbers: SCV0008
40553.1, SCV000840554.1 and SCV000840555.1 (https://www.ncbi.
nlm.nih.gov/clinvar/?term=SCV000840553.1, http://www.ncbi.nlm.
nih.gov/clinvar/?term=SCV000840554.1 and http://www.ncbi.nlm.
nih.gov/clinvar/?term=SCV000840555.1).
Expanded View for this article is available online.
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The paper explained
Problem
Congenital hypothyroidism is the most common endocrine neonatal
disorder with an estimated prevalence of 1/3,500 newborns. It is
mainly caused by defects in thyroid development (thyroid dysgenesis)
or thyroid hormone synthesis. Among patients with congenital
hypothyroidism due to thyroid dysgenesis, the specific genetic cause
is identified only in < 5% of patients. Identifying the molecular defect
allows early clinical care of hypothyroidism and associated malforma-
tions, and provides new insights into thyroid development and
disease.
Results
Using whole exome sequencing, we uncovered an homozygous
missense mutation in TUBB1 gene, in two siblings of a consan-
guineous family with congenital hypothyroidism and thyroid dysgene-
sis (TD). By direct TUBB1 sequencing in a cohort of 270 patients with
TD, we identified two more mutations in two distinct families with
TD. TUBB1 gene encodes for a b1-tubulin, and until now, reported
roles for this protein were confined to platelets. Our functional studies
show TUBB1 expression in the developing and adult thyroid in
humans and mice. The Tubb1/ mice have large platelets and show
hypothyroidism, in accordance with the phenotype in mutated
patients. Thyroids of Tubb1/ exhibited proliferation defects during
early development (embryonic day E9.5), altered migration at E11.5
and E13.5, and failure of hormone secretion at E17.5 and adulthood.
All these mechanisms require proper microtubule function. Interest-
ingly, two of the novel TUBB1 mutations were associated with basal
activation and exaggerated aggregation of platelets.
Impact
This is the first time that TUBB1 mutations are associated with
thyroid dysgenesis, in addition to abnormal platelet physiology. These
findings expand the spectrum of the rare paediatric diseases related
to tubulin mutations and provide new insights into the genetic back-
ground and mechanisms involved in congenital hypothyroidism. A
TUBB1 mutation screening study in patients with non-autoimmune,
non-postsurgical hypothyroidism and altered mean platelet volume
and/or a history of thrombotic disease should be considered.
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